Prof. Stefano Del Prato
School of Medicine, University of Pisa & Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Stefano Del Prato is Professor of Endocrinology and Metabolism at the School of Medicine, University of Pisa and Chief of the Section of Diabetes of the Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. He graduated MD cum laude from the University of Padova and undertook post-graduate specialisation in both Endocrinology and Internal Medicine.
Professor Del Prato’s research interests have always been concerned with diabetes and, in particular, the physiopathology and therapy of type 2 diabetes and insulin resistance syndrome.
He is a member of many societies and associations, including the European Association for the Study of Diabetes (EASD), the American Diabetes Association, and the International Diabetes Federation. He acts as referee for all major journals and has served on the Editorial Boards for the Journal of Clinical Endocrinology and Metabolism, Diabetes Care, and the Journal of Diabetes and Its Complications, Journal of Endocrinological Investigation, and Diabetes & Vascular Disease Research.
Professor Del Prato has published over 500 articles in national and international journals and has been awarded several honours, including the Prize of the Italian Society of Diabetology for outstanding scientific activity. Having served as Vice-President of the EASD from 2011-14, he became President in 2020. He also served as President of Italian Society of Diabetology (2012-14) and as Chairman of the European Foundation for the Study of Diabetes (2015-18).
Duality of Interest: Professor Del Prato has received research support/grants from AstraZeneca and Boehringer Ingelheim and speaker’s fees/honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis Pharmaceutical Company, Novo Nordisk, Sanofi and Takeda Pharmaceuticals. He has also received payments for membership of boards/advisory panels from Abbott, Amarin, Applied Therapeutics, AstraZeneca, Bayer, Eli Lilly & Co, GlaxoSmithKline, Hengrui Pharmaceuticals, Novartis Pharmaceutical Co, Novo Nordisk and Sanofi and consultancy payments from Menarini.
